The BENEFIT Trial: Where Do We Go from Here?

PLoS Negl Trop Dis. 2016 Feb 25;10(2):e0004343. doi: 10.1371/journal.pntd.0004343. eCollection 2016 Feb.

Bernard Pecoul^{1

2}, Carolina Batista^{1

2}, Eric Stobbaerts^{1

2}, Isabella Ribeiro^{1

2}, Rafael Vilasanjuan^{2

3}, Joaquim Gascon^{2

3}, Maria Jesus Pinazo^{2

3}, Silvia Moriana^{2

3}, Silvia Gold^{2

4}, Ana Pereiro^{2

4}, Miriam Navarro^{2

4}, Faustino Torrico^{2

5}, Maria Elena Bottazzi^{2

6}, Peter J Hotez^{2

6}

¹ Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland and Rio de Janeiro, Brazil.
² The Global Chagas Disease Coalition, Barcelona, Spain.
³ IS Global and the Barcelona Centre for International Health Research (CRESIB), Barcelona, Spain.
⁴ Fundacion Mundo Sano, Buenos Aires, Argentina, and Madrid, Spain.
⁵ Fundacion Ceades and Universidad Mayor de San Simon (UMSS), Cochabamba, Bolivia.
⁶ Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine at Baylor College of Medicine, Houston, Texas, United States of America.

No abstract available

Publication types

The author(s) received no specific funding for this work.